PARABILIS MEDICINES, INC. COMMON STOCK

NASDAQ: PBLS (Parabilis Medicines, Inc.)

Last update: 6 hours ago

27.44

-0.18 (-0.67%)

Previous Close 27.63
Volume 1,246,548
Avg. Volume (3M) 975,548
Market Cap 3,437,074,688
Price / Sales 716.26
Price / Book 3.38
52 Weeks Range
22.66 (-17%) — 42.49 (54%)
Earnings Date 12 Nov 2026
Operating Margin (TTM) -8,509.77%
Diluted EPS (TTM) -3.62
Total Debt/Equity (MRQ) 4.16%
Current Ratio (MRQ) 12.88
Operating Cash Flow (TTM) -120.83 M

AIStockmoo Score

0.8
Low debt. Ample short-term liquidity. Negative cash flow. info
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Valuation History info NA
Return on Capital info NA
Earnings Trend info NA
Holdings' Value info NA
Risk Premium info NA
Market Valuation info NA
From our AI technical analysis of the chart. info NA
Trend Strength info NA
Technical Setup info NA
Candle Patterns info NA
No recent price targets, so based on how targets have been revised. info
Recent news mostly positive. info
Holdings' Sentiment info NA
Institutions net +21.81% of shares in their latest 13F filings: 86 holders increased, 20 decreased (quarter to 30 Sep 2026). info
Short interest +100.3% from 31 Aug to 30 Oct 2026, 8.3 days to cover (FINRA). info
Insider Activity info NA
Market environment cautious. info
Sector lagging the market.
The pillars agree, so the score is strengthened.
Below its medium-term trend line. info
Price is low against its 52-week average. Down over 5 years. info
Short-term momentum fading. info
Price is near support. info
Final Score 0.77
Show all

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bullish
Biotechnology (Global) Mixed Bullish
Stock Parabilis Medicines, Inc. - -

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B Score
PBLS 3 B - - 3.38 0.8
LEGN 3 B - - 2.59 -1.6
PVLA 2 B - - 10.82 0.9
MAZE 2 B - - 4.13 0.9
IMCR 1 B - - 3.24 -0.2
GPCR 1 B - - 1.01 -0.8

Select this tab to load the latest available analysis.

Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.

Sector Healthcare
Industry Biotechnology
% Held by Insiders 6.93%
% Held by Institutions 89.48%

Ownership

Name Date Shares Held
Venbio Partners Llc 30 Sep 2026 5,266,697
Regeneron Pharmaceuticals, Inc. 30 Sep 2026 4,166,666

No data within this time range.

Institutions

Institutional ownership: 90.89%

Positions Holders Shares
Increased 86 16,079,357
Decreased 20 344,014
New 60 11,492,551
Sold out 10 178,319

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

Short Interest

Settlement Shares Days to cover
30 Oct 2026 11,052,337 8.3
15 Oct 2026 9,250,099 9.5
30 Sep 2026 8,261,483 4.8
15 Sep 2026 6,092,212 13.3
31 Aug 2026 5,517,704 14.2
14 Aug 2026 5,257,000 15.7

FINRA short interest via Nasdaq, reported twice a month.

2 Positive 0 Negative 1 Neutral
Date Type Details
17 Nov 2026 Yahoo Finance Does Parabilis Medicines (PBLS) Have the Potential to Rally 44.11% as Wall Street Analysts Expect?
The mean of analysts' price targets for Parabilis Medicines (PBLS) points to a 44.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
12 Nov 2026 Yahoo Finance Parabilis Medicines: Q3 Earnings Snapshot
(AP) — Parabilis Medicines Inc. (PBLS) on Thursday reported a loss of $44…
12 Nov 2026 Yahoo Finance Parabilis Medicines Reports Third Quarter 2026 Financial Results and Provides Business Updates
Presented updated Phase 1/2 data at ESMO Congress 2026 demonstrating a 72.2% objective response rate at the 32-week landmark and a favorable safety and tolerability profile for zolucatetide in desmoid tumors Reached alignment with the U.S. FDA on dose, regimen and trial design for upcoming PEDESTAL…
03 Nov 2026 Yahoo Finance Parabilis Medicines to Participate in Upcoming November Investor Conferences
CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced that Mathai Mammen…
24 Oct 2026 Yahoo Finance Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027
Parabilis Medicines (NASDAQ:PBLS) presented updated interim phase I/II data for investigational beta-catenin/TCF inhibitor zolucatetide in desmoid tumors at the European Society for Medical Oncology Congress in Madrid, reporting tumor responses, disease control and an FDA-aligned plan for a registra…
24 Oct 2026 Yahoo Finance Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors
Objective response rate of 72.2% among response-evaluable patients receiving a starting dose of ≥450 mg at 32-week landmarkDisease control rate of 100% across all response-evaluable patients receiving a starting dose of ≥450 mg, with no disease progression and no treatment discontinuations due to…
20 Oct 2026 Yahoo Finance Parabilis Medicines (PBLS) Stock May Trade At A Premium Despite Fresh Zolucatetide Trial Updates
Parabilis Medicines shares have retreated sharply in recent weeks, and that pullback puts fresh focus on what the current price implies relative to the drug developer’s book value. With sentiment swinging around new clinical updates, the key issue is how much of the balance sheet and pipeline risk…
20 Oct 2026 Yahoo Finance Parabilis Medicines (PBLS) Could Be 39% Undervalued As Zolucatetide Trial Expands
Parabilis Medicines (PBLS) has drawn fresh attention after announcing a new dose ranging cohort for its lead drug candidate, zolucatetide, in familial adenomatous polyposis, expanding an ongoing Phase 1/2 trial. The fresh zolucatetide cohort lands in a volatile stretch for Parabilis Medicines, with…
20 Oct 2026 Yahoo Finance What Does Parabilis Medicines (PBLS) Expanding Zolucatetide Into FAP Mean?
Parabilis Medicines (NasdaqGS:PBLS) reported updated Phase 1/2 clinical data for lead candidate zolucatetide in patients with desmoid tumors. The biotechnology company plans to present the new zolucatetide desmoid tumor data at a major oncology congress in 2026. Management has expanded zolucatetide…
19 Oct 2026 Yahoo Finance Parabilis Soars 13% on Upcoming ESMO Data for “First-in-Class” Desmoid Tumor Drug
Key TakeawaysParabilis Medicines shares rose 13% today after the company said it will present updated zolucatetide data in desmoid tumors at ESMO on Saturday, Oct. 24…
19 Oct 2026 Yahoo Finance Parabilis Medicines to Present Updated Clinical Data for Zolucatetide in Patients with Desmoid Tumors at ESMO Congress 2026
Oral presentation will include updated data from the ongoing Phase 1/2 trial, with dose optimization arm designed to inform dose and regimen selection for Phase 3 registrational trial in desmoid tumors Company to host webcast on Saturday, October 24, 2026, at 6 p.m. CEST / 12 p.m. EDT CAMBRIDGE…
14 Oct 2026 Yahoo Finance Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis
New dose-ranging cohort in FAP builds on compelling early clinical evidence observed with zolucatetide in patients with FAP and concomitant desmoid tumors Zolucatetide directly inhibits β-catenin:TCF, targeting the APC-mutation biology that drives precancerous adenomatous polyp formation in…
13 Oct 2026 Yahoo Finance Phanes Therapeutics to participate in Longwood Healthcare Leaders Boston CEO, November 2-3, 2026
Phanes Therapeutics, Inc. (Phanes), a clinical-stage biotech company focused on innovative drug discovery and development in immuno-oncology (IO), announced that Ming Wang (CEO) will participate in Boston CEO, November 2-3, 2026, at the Mandarin Oriental Hotel in Boston, MA. He will speak on a…
28 Sep 2026 Yahoo Finance Sixty Degree Capital Extends Its Track Record as Five Portfolio Companies Enter the Public Markets in 2026
Sixty Degree Capital ("SDC"), a global, multi-stage venture capital firm investing across technology and healthcare, continued its strong portfolio momentum in 2026. Building on the firm's history of successful exits, five SDC portfolio companies have completed initial public offerings in 2026…
23 Sep 2026 Yahoo Finance MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
LONDON and NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the appointment of Alan M. Sebulsky to its Board of Directors. Mr. Sebulsky is a veteran healthcare portfolio manager and…
01 Sep 2026 Yahoo Finance Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced its Chairman, President…
25 Aug 2026 Yahoo Finance Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors
CAMBRIDGE, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced the appointment of Craig…
24 Aug 2026 Yahoo Finance Young startups miss out on biotech venture funding rebound, MassBio says
A new report found that the sizes of seed rounds and Series A financings for Massachusetts biotech startups are going in opposite directions, as funding slows for young companies with the “riskiest science.”
Show more

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Risk / Reward
TP1:
TP2:

Loss to SL against profit to each target, from EP. A ratio of 2 or more is usually sought.

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria